Y-Mabs Therapeutics Receivables

Y-Mabs Therapeutics's receivables stands at $16M as of June 2025. That compares with $38M in the prior-year period — down 58.8% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Y-Mabs Therapeutics reported $16M in receivables versus $38M a year earlier — a 58.8% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $38M in the prior-year period — down 58.8% year over year. Sustained growth in receivables can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Y-Mabs Therapeutics's receivables evolved across reporting periods, while the comparison chart places YMAB next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, receivables is commonly used to spot outliers. Y-Mabs Therapeutics's reading of $16M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.